Global $172.8 Bn End Stage Renal Disease Markets, 2021-2027 by Disease Type, Treatment Type, End User, Geography, Competitive Analysis - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global End Stage Renal Disease Market (2021-2027) by Disease Type, Treatment Type, End User, and Geography. IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global End Stage Renal Disease Market is estimated to be USD 83 Bn in 2021 and is expected to reach USD 172.8 Bn by 2027, growing at a CAGR of 13%.

The increasing number of patients suffering from kidney failure and the introduction of technologically advanced products, such as low maintenance dialysis equipment and artificial kidney, are the major factors expected to drive the end stage renal disease (ESRD) market. The ongoing Covid-19 pandemic has resulted in an increased demand for home dialysis across the globe.

Market Segmentation

• By Disease Type, the market is classified as Chronic Kidney Disease and End stage renal disease.
• By Treatment, the market is classified as Dialysis, Medication and kidney transplantation. Dialysis is more convenient and easier to obtain for a patient with ESRD and the whole process can be done at a dialysis center or at home.
• By End User, the market is classified as Dialysis centers, hospitals, clinics and research and academic institutes.
• By Geography, Asia Pacific is projected to lead the market.

Company Profiles

• Nipro Corporation
• Fresenius Medical Care AG & Co. KGaA
• Baxter International, Inc.
• Medtronic Plc
• B. Braun Melsungen AG
• BD
• Asahi Kasei Medical Co., Ltd.
• Cantel Medical
• Nikkiso Co., Ltd.
• JMS Co. Ltd.
• Abbott
• Amgen Inc.
• AstraZeneca
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• Fresenius Medical Care AG & Co.
• GlaxoSmithKline PLC
• Keryx Biopharmaceuticals, Inc
• Kissei Pharmaceutical Co., Ltd
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Ltd

Key Topics Covered:

1 Report Description

1.1 Study Objectives

1.2 Market Definition

1.3 Currency

1.4 Years Considered

1.5 Language

1.6 Key Stakeholders

2 Research Methodology

2.1 Research Process

2.2 Data Collection and Validation

2.3 Market Size Estimation

2.4 Assumptions of the Study

2.5 Limitations of the Study

3 Executive Summary

4 Market Overview

4.1 Introduction

4.2 Market Dynamics

4.2.1 Drivers

4.2.1.1 Growing prevalence of diabetes and hypertension

4.2.1.2 Introduction of technologically advanced products

4.2.1.3 Increasing number of patients suffering from chronic kidney disease

4.2.2 Restraints

4.2.2.1 Risk of complications

4.2.2.2 Stringent regulatory policies for dialysis products

4.2.3 Opportunities

4.2.3.1 High Focus on technology

4.2.3.2 R&D

4.2.4 Challenges

4.2.4.1 Lack of infrastructure availability in emerging countries

4.3 Trends

5 Market Analysis

5.1 Porter's Five Forces Analysis

5.2 Impact of COVID-19

5.3 Ansoff Matrix Analysis

6 Global End Stage Renal Disease Market, By Disease Type

6.1 Chronic Kidney Disease

6.2 End-Stage Renal Disease (ESRD)

7 Global End Stage Renal Disease Market, By Treatment Type

7.1 Dialysis

7.2 Medication

7.3 Kidney Transplantation

8 Global End Stage Renal Disease Market, By End Users

8.1 Dialysis Centres

8.2 Hospital & Clinics

8.3 Research and Academic Institutes

9 Global End Stage Renal Disease Market, By Geography

9.1 Introduction

9.2 North America

9.2.1 US

9.2.2 Canada

9.2.3 Mexico

9.3 South America

9.3.1 Brazil

9.3.2 Argentina

9.4 Europe

9.4.1 UK

9.4.2 France

9.4.3 Germany

9.4.4 Italy

9.4.5 Spain

9.4.6 Rest of Europe

9.5 Asia-Pacific

9.5.1 China

9.5.2 Japan

9.5.3 India

9.5.4 Indonesia

9.5.5 Malaysia

9.5.6 South Korea

9.5.7 Australia

9.5.8 Russia

9.5.9 Rest of APAC

9.6 Rest of the World

9.6.1 Qatar

9.6.2 Saudi Arabia

9.6.3 South Africa

9.6.4 United Arab Emirates

9.6.5 Latin America

10 Competitive Landscape

10.1 Competitive Quadrant

10.2 Market Share Analysis

10.3 Competitive Scenario

10.3.1 Mergers & Acquisitions

10.3.2 Agreement, Collaborations, & Partnerships

10.3.3 New Product Launches & Enhancements

10.3.4 Investments & Funding

11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/n6fkaf

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900